Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease
NCT00868855
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
16
Enrollment
OTHER
Sponsor class
Stopped
poor enrollment
Conditions
Coronary Artery Disease
Interventions
DRUG:
Bradykinin
Sponsor
Vanderbilt University